These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 7995947)

  • 41. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
    Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
    In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
    Siders WM; Wright PW; Hixon JA; Alvord WG; Back TC; Wiltrout RH; Fenton RG
    J Immunol; 1998 Jun; 160(11):5465-74. PubMed ID: 9605149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Experimental study on the treatment of human hepatocellular carcinoma by fibroblast-mediated human IFN-alpha gene therapy in combination with adoptive chemoimmunotherapy].
    Wang J; Cao X; Kong X
    Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):266-70. PubMed ID: 7587892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice.
    Bubeník J; Lotzová E; Indrová M; Simová J; Jandlová T; Savary CA
    Nat Immun Cell Growth Regul; 1991; 10(5):247-55. PubMed ID: 1758466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma.
    Kimura Y; Mizuno H; Satake K; Tahara H; Tsukuda M
    Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1181-5. PubMed ID: 14623747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
    Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
    Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
    Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
    Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets.
    Sung MW; Nagashima S; Johnson JT; Van Dongen GA; Whiteside TL
    Cell Immunol; 1996 Jul; 171(1):20-9. PubMed ID: 8660833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
    Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery.
    Da Costa ML; Redmond HP; Bouchier-Hayes DJ
    J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
    Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
    Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
    Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.